BridgeBio reported data showing its oral FGFR3 inhibitor infigratinib achieved height outcomes comparable to Voxzogo in achondroplasia, positioning an oral therapy as an alternative to existing treatment options. The dataset, covered by BioCentury, indicates infigratinib may offer a non-injectable pathway to target FGFR3-driven growth impairment. BridgeBio is preparing regulatory submissions informed by the head-to-head efficacy signal and convenience advantages of oral dosing. The company will need safety and long-term growth data to convince regulators and payers to accept an oral alternative. Clinicians and parents seeking less invasive chronic therapies will watch safety, durability of response, and growth plate effects. If regulators clear an oral option, the treatment landscape for FGFR3-driven short stature could shift toward differentiated administration modalities.